Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study

References

• Briggs AM, Cross MJ, Hoy DG, Sanchez-Riera L, Blyth FM, Woolf AD, et al. Musculoskeletal health conditions represent a global threat to healthy aging: a report for the 2015 World Health Organization World Report on Ageing and Health. Gerontologist. 2016;56(Suppl 2):S243–S55.
   PubMedGoogle Scholar
• Bevan S. Economic impact of musculoskeletal disorders (MSDs) on work in Europe. Best Pract Res Clin Rheumatol. 2015;29(3):356–73.
   PubMed Web of Science ®Google Scholar
• Verstappen SM. Rheumatoid arthritis and work: the impact of rheumatoid arthritis on absenteeism and presenteeism. Best Pract Res Clin Rheumatol. 2015;29(3):495–511.
   PubMed Web of Science ®Google Scholar
• Tang K, Beaton DE, Boonen A, Gignac MA, Bombardier C. Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI). Arthritis Care Res. 2011;63:S337–S49.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24(1):33–40.
   PubMed Web of Science ®Google Scholar
• Sruamsiri R, Mahlich J, Tanaka E, Yamanaka H. Productivity loss of Japanese patients with rheumatoid arthritis – a cross-sectional survey. Mod Rheumatol. 2018;28(3):482–9.
   PubMed Web of Science ®Google Scholar
• Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731–40.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–7.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–23.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kameda H, Saito K, Kaneko Y, Tanaka E, Yasuda S, et al. Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC Study. Arthritis Res Ther. 2018;20(1):151.
   PubMedGoogle Scholar
• Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.
   PubMed Web of Science ®Google Scholar
• Smolen JS, , Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, for the T2T Expert Committee, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.
   PubMed Web of Science ®Google Scholar
• Tocilizumab package insert for Japan. Available from: https://chugai-pharm.jp/hc/ss/pr/drug/act_via0200/pi/PDF/act_pi.pdf [last accessed 13 Dec 2018].
   Google Scholar
• Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis A. Validity of the work productivity and activity impairment questionnaire – general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R177.
   PubMed Web of Science ®Google Scholar
• Fujino Y, Uehara M, Izumi H, Nagata T, Muramatsu K, Kubo T, et al. Development and validity of a work functioning impairment scale based on the Rasch model among Japanese workers. J Occup Health. 2015;57(6):521–31.
   PubMed Web of Science ®Google Scholar
• Shiratsuchi M, Saeki S, Hachisuka K. Japanese version of the self-rating Frenchay Activities Index and its clinical application and standard values. Gen Rehab. 1999;27:469–74.
   Google Scholar
• Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set. The case of Japan. Health Econ. 2002;11(4):341–53.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49(6):784–8.
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Kessler R, Slade T, Andrews G. The performance of the K6 and K10 screening scales for psychological distress in the Australian National Survey of Mental Health and Well-Being. Psychol Med. 2003;33(2):357–62.
   PubMed Web of Science ®Google Scholar
• Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17(1):45–56.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Nakajima R, Komatsu S, Yamazaki K, Nakamura T, Agata N, et al. Impact of adalimumab on work productivity and activity impairment in Japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study. Adv Ther. 2017;34(3):686–702.
   PubMed Web of Science ®Google Scholar
• Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, et al. Tapering DMARD therapy in rheumatoid arthritis – current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428–37.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172–80.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.
   PubMed Web of Science ®Google Scholar
• Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019.
   PubMed Web of Science ®Google Scholar
• Kojima M, Kojima T, Suzuki S, Takahashi N, Funahashi K, Asai S, et al. Patient-reported outcomes as assessment tools and predictors of long-term prognosis: a 7-year follow-up study of patients with rheumatoid arthritis. Int J Rheum Dis. 2017;20(9):1193–200.
   PubMed Web of Science ®Google Scholar
• de Wit MP, Kvien TK, Gossec L. Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. RMD Open. 2015;1(1):e000129.
   PubMed Web of Science ®Google Scholar
• Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum. 1987;30(5):507–12.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998;25(11):2108–17.
   PubMed Web of Science ®Google Scholar
• Langley PC, Mu R, Wu M, Dong P, Tang B. The impact of rheumatoid arthritis on the burden of disease in urban China. J Med Econ. 2011;14(6):709–19.
   PubMedGoogle Scholar
• Kingsley G, Scott IC, Scott DL. Quality of life and the outcome of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25(4):585–606.
   PubMed Web of Science ®Google Scholar